Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study.
Matthias Preusser, Tomáš Kazda, Emilie Le Rhun...
https://pubmed.ncbi.nlm.nih.gov/38849943/Actively Recruiting
Led by European Organisation for Research and Treatment of Cancer - EORTC · Updated on 2026-06-08
411
Participants Needed
45
Research Sites
21 weeks
Total Duration
Researchers are studying patients with first progression or recurrent glioblastoma, a type of brain tumor that often returns despite initial treatment. This study aims to compare the effectiveness of lomustine alone versus lomustine combined with reirradiation to see if the combination can improve overall survival without reducing quality of life. The study is a randomized Phase III trial sponsored by the European Organisation for Research and Treatment of Cancer and will include patients who have had prior standard chemoradiotherapy and meet specific health criteria. Participants will be randomly assigned to one of two groups one receiving lomustine alone and the other receiving lomustine plus reirradiation. Lomustine is given orally, while reirradiation is administered at least six months after the previous radiotherapy. The trial includes planned interim analyses to evaluate the effectiveness and safety of the treatments. During the study, participants will be closely monitored through overall survival assessments up to 40 months after enrollment. Researchers will also track progression-free survival, health-related quality of life, toxicity profiles, neurocognitive functioning, and treatment responses. Safety and quality of life will be assessed throughout the treatment and follow-up periods, ensuring comprehensive evaluation of the combined therapy compared to lomustine alone.
CONDITIONS
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
E
EORTC
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
European Organisation for Research and Treatment of Cancer - EORTC
Lead Sponsor
Swiss Cancer Institute
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 40 months or until disease progression or discontinuation
Participants receive Lomustine with or without reirradiation as treatment for first progression of glioblastoma.
Regular visits during treatment as per protocol
Duration - Up to 40 months from enrollment
Participants are monitored for overall survival and quality of life after treatment ends.
Visits scheduled according to study follow-up protocol
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Matthias Preusser, Tomáš Kazda, Emilie Le Rhun...
https://pubmed.ncbi.nlm.nih.gov/38849943/European Organisation for Research and Treatment of Cancer - EORTC
Lead Sponsor
Swiss Cancer Institute
Collaborating Sponsor